Libby's H*O*P*E*

*Helping*Ovarian Cancer Survivors*Persevere Through*Education

Menu

Skip to content
  • Home
  • About
  • Mission
  • Warning Signs & Symptoms
  • Ovarian Cancer Overview
  • Prevention, Early Detection/Screening & Causes
  • Genetics
  • Types of Ovarian Cancer
  • Diagnosis & Staging
  • Treatment Overview
  • Surgery
  • Chemotherapy
  • Radiology & Radiation Therapy
  • Hormonal (Anti-Estrogen) Therapy
  • Biological (Immunotherapy & Vaccine) Therapy
  • Gene Therapy
  • Alternative & Complementary Therapy
  • Clinical Development
  • Clinical Trials
  • Coping
  • Survivorship
  • Ovarian Cancer Resources
  • Contact

Tag Archives: James P. Wilmot Cancer Ctr.

Ginger Quells Cancer Patients’ Chemotherapy-Related Nausea

Posted on May 16, 2009 by Paul Cacciatore

“People with cancer can reduce post-chemotherapy nausea by 40 percent by using ginger supplements, along with standard anti-vomiting drugs, before undergoing treatment, according to scientists at the University of Rochester Medical Center. …”

Continue reading →

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on Pinterest (Opens in new window) Pinterest
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Reddit (Opens in new window) Reddit
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email
Like Loading...
Posted in Alternative Medicine, Chemotherapy, Coping, Meeting Highlights | Tagged 2009 ASCO Annual Mtg., Anzemet, Community Clinical Oncology Program Research Base, Complementary & Alternative Medicine, ginger, James P. Wilmot Cancer Ctr., Julie L. Ryan Ph.D. M.P.H., National Cancer Institute, Novaban, ovarian cancer, Univ. of Rochester Medical Ctr., Zofran | Leave a comment
"Once you choose hope, anything is possible." -- Christopher Reeve

Categories

RSS Google Ovarian Cancer News

  • Nearly half of ovarian cancer cases are diagnosed in ER, missing critical treatment window, study finds - ABC News - Breaking News, Latest News and Videos
  • Sprinting for a Cure: Annual event funds ovarian cancer research at UCLA - Los Angeles Downtown News
  • PRC2 governs HR proficiency and chemosensitivity in ovarian cancer via SQSTM1-mediated chromatin ubiquitination - Nature
  • Runcie C.W. Chidebe: Last Call for Nominations for the World Ovarian Cancer Coalition Impact Awards 2026 - Oncodaily
  • Six years, one lab: How a summer internship led to a Ph.D. in ovarian cancer research - University of Arizona News
  • Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026 - Targeted Oncology
  • Personalized ovarian cancer vaccines spark immunity in phase 1 trial - Medical Xpress
  • Rinatabart Sesutecan for Patients With Platinum-Resistant Ovarian Cancer: First Efficacy and Safety Results From the Phase 2 Cohort of the RAINFOL-01 Study - OncLive
  • ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space - Fierce Biotech
  • The surprising link between ovarian cancer and the fallopian tubes - Harvard Health

Top Posts

  • CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists.
    CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists.
  • About
    About
  • 2009-2010 U.S. News & World Report Best U.S. Hospital Rankings
    2009-2010 U.S. News & World Report Best U.S. Hospital Rankings
  • The Mirror: "What is the Meaning of Life?"
    The Mirror: "What is the Meaning of Life?"
  • Warning Signs & Symptoms
    Warning Signs & Symptoms
  • NOCC to Host Annual "Walk To Break The Silence On Ovarian Cancer" in the Greater Washington, D.C. Area
    NOCC to Host Annual "Walk To Break The Silence On Ovarian Cancer" in the Greater Washington, D.C. Area
  • Ovarian Cancer Overview
    Ovarian Cancer Overview
  • M.D. Anderson Study Predicts Dramatic Growth in Cancer Rates Among U.S. Elderly, Minorities
    M.D. Anderson Study Predicts Dramatic Growth in Cancer Rates Among U.S. Elderly, Minorities
  • Can Talcum Powder Cause Ovarian Cancer?
    Can Talcum Powder Cause Ovarian Cancer?
  • Combination Targeted Therapy With Sorafenib & Bevacizumab Shows Antitumor Activity
    Combination Targeted Therapy With Sorafenib & Bevacizumab Shows Antitumor Activity

Archives

  • May 2015
  • September 2014
  • August 2014
  • May 2014
  • March 2014
  • August 2013
  • May 2013
  • February 2013
  • January 2013
  • July 2012
  • June 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008

Blog Stats

  • 514,837 Visitors
cancer blog

Enter your email address to subscribe to Libby's H*O*P*E* & receive notifications of new posts by email.

Join 341 other subscribers

 Subscribe in a reader

Click on the orange button above if you want to (i) add Libby's H*O*P*E*(tm) updates to a web-based or other reader, or (ii) embed a Libby's H*O*P*E* (tm) update widget on your desktop, website or blog.

Donate To Ovarian Cancer Research

OCRF is the largest U.S. private funding agency supporting ovarian cancer research. It is a not-for-profit, 501(c)(3) organization. Click on the OCRF logo above to make a donation.

Strategic Partners

Podcasts

Join Us In the Fight Against Ovarian Cancer

RSS New Ovarian Cancer Clinical Trials (Past 14 Days)

  • Phase 1 Study of VT-101 in Advanced Ovarian Cancer
  • Methylation Profiling in Self-samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
  • A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
  • Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy
  • A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
  • Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors

RSS New Adult Solid Tumor Clinical Trials (Past 14 Days)

  • A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
  • Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
  • A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
  • First-in-Human, Multicenter, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of YL-18319 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors
  • A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
  • A Study of BON-C1393 in Adults With Advanced Solid Tumors
  • Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
  • SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
  • A Study of IBI3043 Treatment in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
  • Phase 1 Study of VT-101 in Advanced Ovarian Cancer

RSS Medical Studies

  • Advances and hot topics in the treatment of epithelial ovarian cancer
  • Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer
  • Interleukin-37 in cancer: Context-dependent roles in tumor immunity, prognosis, and therapeutic targeting
  • CT-based adaptation of the Vizzielli laparoscopic risk-adjusted score in advanced ovarian cancer: Agreement and inter-reader reproducibility
  • Thoracic recurrence after complete gross resection in advanced ovarian cancer: The clinical impact of occult subdiaphragmatic lymphatic invasion
  • Defining quality care in gynecologic cancers: A Society of Gynecologic Oncology review
  • How patients with advanced gynecological cancer perceive clinicians' attention to their values, wishes, and needs: a qualitative study
  • Clinical outcomes of 5-day administration of topotecan combined with bevacizumab for platinum-resistant ovarian cancer: a multicenter retrospective analysis
  • Near-Infrared Light-Responsive Liposomes for Modulating Switchable CAR-T Cell Therapy
  • Mechanical dysfunction: ovarian cancer ascites disables NK cells by suppressing CDC42-driven force generation

Recent Comments

Prometey Bank's avatarPrometey Bank on World Ovarian Cancer Day: Toge…
mikaljhohnashly's avatarmikaljhohnashly on World Ovarian Cancer Day: Toge…
Jan C. Calthrop's avatarJan C. Calthrop on Lab-On-A-Chip: Veridex & M…
Paul Cacciatore's avatarPaul Cacciatore on About
Building a Team for… on About
Kathleen's avatarKathleen on About
Paul Cacciatore's avatarPaul Cacciatore on About
Liz's avatarLiz on About
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Judith Marengere's avatarJudith Marengere on Dana Farber Webchat: The Lates…
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Franca Pichini's avatarFranca Pichini on Dana Farber Webchat: The Lates…
painspeaks's avatarpainspeaks on SU2C Announces the Formation o…
marcy westerling's avatarmarcy westerling on SU2C Announces the Formation o…
anne's avataranne on Dana-Farber Oncologists Differ…

Blogroll

  • Site Meter Site Meter

Cancer Organizations

  • American Cancer Society
  • National Cancer Institute

Everyday Heroes

  • Are You There Cancer? It's Me, Jennie.
  • Bald Heads Are Sexy
  • Butterfly Ballet
  • Cancer Queen
  • Carrie's Journey
  • Chris Bledy
  • Diary of a Cancer Patient
  • I Want To Breathe
  • Janine's News
  • Journey Through Ovarian Cancer
  • Kristi & Brian: Living! With Cancer
  • Laurey Bikes
  • Life Cycle
  • livingly dying
  • Marcheline Bertrand Remembered
  • Meghan's Message
  • Monday Hearts For Madalene
  • My Journey With Teal
  • Nobody Has Ovarian Cancer
  • Out Shine Ovarian Cancer
  • OVACOM
  • Ovarian Cancer News
  • Ovarian Cancer?? pass the wine … now!
  • Scrambled Eggs, Surviving Ovarian Cancer
  • Shannon Miller Lifestyle
  • Still Smiling
  • Strong As Steele
  • Tenaciously Teal
  • The Carcinista
  • What? Me Worry?
  • Will There Be Cows In Heaven?
  • Women of Teal

Inspirational Cancer Advocates

  • Bald Is Beautiful
  • Bicycling For Ovarian Cancer (Craig Broeder)
  • Christine Druther
  • Fran Drescher
  • Imerman Angels
  • Jenn Sommermann: Training For a Cure
  • Jim Valvano
  • Laurey Masterton
  • Maddie Kullen
  • Mothers With Cancer
  • Randy Pausch
  • Sean Swarner
  • Standup2cancer
  • The Rock Band N.E.D.

Ovarian Cancer News Archive

  • Ovarian Cancer News Archive

Ovarian Cancer Organizations

  • National Breast & Ovarian Cancer Connection
  • National Ovarian Cancer Coalition
  • Ovarian Cancer National Alliance
  • Ovarian Cancer Research Fund
  • Ovations For the Cure

U.S. Treatment Centers

  • National Comprehensive Cancer Network Member Institutions
  • NCI-Designated Cancer Centers

Video Archive

  • Ovarian Cancer Video Library
Copyright 2008 - 2016 Paul Cacciatore, Libby's H*O*P*E*(TM), *Helping *Ovarian Cancer Survivors *Persevere Through *Education(TM), all rights reserved.
Paul Cacciatore

Create Your Badge
Site Meter
Blog at WordPress.com.
  • Subscribe Subscribed
    Libby's H*O*P*E*
    Join 216 other subscribers

    Have a WordPress.com account? Log in now.

  • Libby's H*O*P*E*
    View site in Reader
    Manage subscriptionsSign upLog in
    Report this content
    Collapse this bar
%d